TAI'AN, China, Sept. 16, 2011 /PRNewswire-Asia-FirstCall/ --
China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or
the "Company"), a leading plasma-based biopharmaceutical company in
China, today announced that it
will present at the UBS Global Life Sciences Conference in
New York on September 19.
Mr. Tristan Kuo, China Biologic's
Chief Financial Officer, will present at the conference on
Monday, September 19, 2011 at
2:00 p.m. in the Grand Hyatt New
York, 109 East 42nd Street at Grand Central Terminal, New York, NY.
Institutional investors interested in meeting with Mr. Kuo
during the conference should please contact their UBS sales
representative.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products
Co., Ltd., and Guiyang Dalin Biologic Technologies Co., Ltd., and
its equity investment in Xi'an Huitian Blood Products Co., Ltd., is
currently one of the leading plasma-based biopharmaceutical
companies in China.
China Biologic is a fully integrated biologic products company
with plasma collection, production and manufacturing, research and
development, and commercial operations. The Company's plasma-based
biopharmaceutical products are irreplaceable during medical
emergencies and are used for the prevention and treatment of
various diseases. The Company sells its products to hospitals and
other healthcare facilities in China. Please see the Company's website at
www.chinabiologic.com for additional information.
Company
Contact
|
|
|
|
Mr. Y. Tristan
Kuo
|
|
Chief Financial
Officer
|
|
China Biologic Products,
Inc.
|
|
Tel: +86 53 8620
2206
|
|
Email: IR@chinabiologic.com
|
|
www.chinabiologic.com
|
|
|
SOURCE China Biologic Products, Inc.